In this study, we show the expression and purification of the human recombinant farnesoid X receptor (FXR)-ligand binding domain (LBD) protein in E. coli using a double cistronic vector, pACYCDuet-1, as a soluble form. We describe here the expression and characterization of a biologically active FXR-LBD . When expressed in the influence of bacterial promoters (P T7 and P Tac ) of the single cistronic expression vectors, the human recombinant FXR-LBD (248-476) was found to be totally insoluble. However, by using a double cistronic expression vector, we were able to obtain the human recombinant FXR-LBD in a soluble form. To allow for biological activities, we have subcloned into the pACYCDuet-1 vector, expressed in E. coli cells at some optimized conditions, and purified and characterized the human recombinant active FXR-LBD proteins using the fluorescence polarization assay. This suggests that the expression of FXR-LBD in a double cistronic vector improves its solubility and probably assists its correct folding for the biologically active form of the proteins. We suggest that this may represent a new approach to high expression of other nuclear receptors and may be useful as well for other classes of heterodimeric protein partners.
Members of the nuclear receptor superfamily including the receptors for retinoic acid, vitamin D, thyroid hormones, and steroid hormones are hormone-activated transcription factors that play important roles in a vast range of physiological processes [2, 13, 16, 17] . The hormone nuclear receptor superfamily includes different proteins responsible for the direct link between transcriptional regulation and physiological responses [1, 18] . The activity of subgroups of nuclear receptors is regulated by small lipophilic, membrane permeable ligands, making them ideal drug targets [2, 19] . Indeed, 13% of all FDA-approved drugs target nuclear receptors and are used for treatment of a wide range of diseases, such as metabolic syndromes, inflammation, and cancer [1, 22] . Originally discovered as receptors for steroid hormones, the nuclear receptor family also encompasses metabolic receptors. The metabolic nuclear receptors act as metabolic and toxicological sensors, enabling the organism to quickly adapt to metabolic changes by inducing/repressing the appropriate genes and pathways [4] .
Bile acids are important signaling molecules that are involved in the regulation of the metabolism, energy expenditure, and glucose homeostasis. Bile acid synthesis in hepatocytes provides a metabolic pathway for the catabolism of cholesterol, and their detergent properties promote the solubilization of dietary fats and fat-soluble vitamins in the small intestine [9] . However, owing to their amphipathic nature, bile acids are toxic in high concentrations. In response to elevated levels of intracellular bile acids, activated farnesoid X receptor (FXR) induces protective gene expression circuits against bile acid toxicity in the liver and intestine. In addition, it has become clear that an additional pivotal role for FXR consists of downregulating genes involved in inflammation [7] . Thus, bile acids and their nuclear receptor, FXR, regulate inflammatory responses and barrier function in the intestinal tract.
The nuclear receptors share a common structure, with an N-terminal activation function domain, a DNA binding domain, connected by a flexible hinge to the ligand binding domain (LBD), which changes conformation upon ligand binding [3, 30] . The ligand-dependent activation function at the C-terminus of most nuclear receptors allows them to sense metabolic changes within cells, and *Corresponding author Phone: +82-43-840-3903; Fax: +82-43-852-3616; E-mail: byoung1@kku.ac.kr orchestrates rapid transcriptional changes in response. The FXR (encoded by Nr1h4) is a member of the nuclear receptor superfamily and a receptor for bile acids, whose activation leads to alterations in cellular pathways involved in energy metabolism [7, 15, 23, 27] . FXR binds to FXR response elements either as a monomer or as a heterodimer with the retinoid X receptor α (RXRα) [10, 25] . FXR is expressed mainly in the liver, intestine, kidneys, and adrenal gland, with less expression in adipose tissue and heart [12, 14] . Conformational changes induced by bile acid lead to increased expression of a wide variety of genes [20] . These changes lead to decreased intracellular bile acid concentrations through multiple mechanisms including decreased bile acid synthesis from cholesterol, decreased hepatocellular uptake, and increased secretion into bile. Physiologically, FXR counteracts liver X receptor (LXR) in both cholesterol and triglyceride metabolism [21] . Thus, it is accepted that FXR is a master regulator in bile acid homeostasis. Subsequently, novel functions of FXR have been identified including protecting the intestinal barrier and modulating the innate immunity and tumorigenesis [5, 6, 29] . Hence, the identification of FXR-selective agonists may be of significant therapeutic value.
In this study, we aimed to express and purify the human recombinant FXR-LBD (248-476) (rFXR-LBD) protein in E. coli using a commercially available double cistronic pACYCDuet-1 vector. When expressed under the influences of bacterial promoters of single cistronic expression vectors, the rFXR-LBD was found to be totally insoluble. However, by using a double cistronic expression system, we were able to obtain high levels of soluble rFXR-LBD. Although the real mechanism of this phenomenon is obscure, this suggests that the expression of rFXR-LBD using the pACYCDuet-1 TM dual cistronic expression vector improves its solubility and probably assists its correct folding working as a molecular chaperone.
MATERIALS AND METHODS

Preparation of Expression Constructs
For the expression of FXR-LBD , cDNA fragments encoding human FXR-LBD were obtained by RT-PCR and subcloned into the pET-15b (at BamHI site, driven by P T7 promoter; Merck KGaA, Darmstadt, Germany), pTAC-MAT-Tag-1 (at HindIII/SmaI sites, driven by P Tac promoter; Sigma-Aldrich Co., St. Louis, MO, USA), and pACYCDuet-1 (driven by P T7 promoter; Merck KGaA) vectors (Fig. 1) . For the pTAC-MAT-Tag-1 vector, FXR-LBD was fused with a metal affinity tag (MAT; HNHRHKH) at its Nterminus and subcloned into the HindIII/SmaI sites. For the pACYCDuet-1 vector, FXR-LBD (248-476) was inserted into MCS 1 at the BamHI/HindIII sites for expression as the (His) 6 -fused protein (Fig. 1) . All constructs were confirmed by DNA sequencing. The oligonucleotide primers used for PCR-based cloning are shown in Table 1 . All molecular works for construction of expression plasmids were performed by the standard procedures.
Protein Expression and Purification
The expression constructs for human FXR-LBD in pET-15b, pTAC-MAT-Tag-1, and pACYCDuet-1 were transformed into E. coli BL21 (DE3) Pro cells (Invitrogen, Carlsbad, CA, USA). Cultures were grown at 37 o C in LB medium containing antibiotics. These cultures were induced at an optical density at 600 nm of 0.8-1.0 using 0.5 mM isopropyl β-D-thiogalactopyranoside (IPTG) and grown for a further 5-6 h before harvesting by centrifugation. The collected cell pellets were resuspended in Buffer A containing was fused to (His) 6 at its N-terminal and subcloned into the 1 st multiclonal site, whereas no gene was subcloned into the 2 nd site.
